We’re pursuing every opportunity to develop and bring our investigational drugs to patients
ARENA PUBLICATIONS ARCHIVE
View publications for detailed data on our investigational drugs
These scientific publications are provided for educational purposes only. They may discuss or mention Arena investigational drugs, which have not been approved by any health authority. Additional studies are required to make any definitive conclusions about safety or efficacy.
While listed posters/abstracts were accepted for presentations at medical congresses, these have not been subjected to full peer review and present only initial, preliminary findings, which may differ from those that could appear in later, complete manuscripts and peer-reviewed publications.
Choose either Key Topics or Congresses to search our database.
Etrasimod, a novel sphingosine-1-phosphate (S1P) receptor modulator, lacks functional activity at S1P2 receptors
ASPET, 2017
Etrasimod (APD334), an oral, next-generation sphingosine-1-phosphate receptor modulator inhibits the development of colitis in lymphoid-null mice injected with colitogenic CD4+ T cells
ASPET, 2017Functional activity of etrasimod and a diverse panel of sphingosine-1-phosphate receptor (S1PR) modulators at S1P4 receptors
ASPET, 2017Preclinical safety assessment of etrasimod (APD334), an oral sphingosine-1-phosphate receptor (S1P) modulator with a favorable profile
AIBD, 2016The sphingosine-1-phosphate receptor (S1P) modulator etrasimod (APD334) demonstrates limited effects on heart rate in preclinical testing
AIBD, 2016Olorinab (APD371), a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2), reduces colitis-induced visceral hypersensitivity in rats
IASP, 2018APD371: a potent, highly selective, full agonist of the human CB2 receptor with sustained analgesic effects in rodents
APS, 2018Discovery of APD371: identification of a highly potent and selective CB2 agonist for the treatment of chronic pain
ACS Med Chem Lett, 2017Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid type 2 receptor (CB2), reduces visceral hypersensitivity in animal models
DDW, 2019Olorinab, a peripherally restricted, highly selective agonist of the cannabinoid receptor type 2 for the management of visceral pain in inflammatory bowel disease (IBD)—preclinical and early clinical development
Crohn's & Colitis Congress, 2019Olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), reduces visceral hypersensitivity in mice
DDW, 2020Expression and localization of cannabinoid receptors and the effect of olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, on visceral hypersensitivity in rodent models of irritable bowel syndrome and inflammatory bowel disease
UEG, 2020Cannabinoid receptor 2 (CB2) localization in colonic tissue and primary sensory dorsal root ganglia (DRG) neurons isolated from rodents with colitis and chronic visceral hypersensitivity
DDW, 2021Modulation of sphingosine-1-phosphate in inflammatory bowel disease
Autoimmun Rev, 2017Patient-reported disease activity in a large sample of ulcerative colitis (UC) patients using social media-delivered questionnaires
ACG, 2020Patient-reported disease activity in a large sample of ulcerative colitis (UC) patients using social media-delivered questionnaires
ECCO, 2020The incremental rate of thromboembolic events in patients with inflammatory bowel disease compared to patients without immune-mediated diseases
ACG, 2020The incremental rate of thromboembolic events in patients with inflammatory bowel disease compared to patients without immune-mediated diseases
UEG, 2020Examining the link between autoimmune disease and thromboembolic events: a modified Delphi panel approach
ACG, 2020Risk factors for thromboembolic events among patients with immune-mediated diseases
ACG, 2020The economic burden of thromboembolic events among patients with inflammatory bowel disease
DDW, 2021Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010–2019
Drug Saf, 2021Immune-mediated diseases and thromboembolic events: a modified Delphi panel
Curr Med Res Opin, 2021Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases
Clin Ther, 2021Mass balance, metabolic disposition, and pharmacokinetics of [14C]etrasimod following oral administration to healthy male volunteers
AAPS PharmSci 360, 2019Safety, pharmacokinetics and pharmacodynamics of etrasimod (APD334), an oral, selective S1P receptor modulator, after single dose escalation in healthy volunteers
AIBD, 2016Etrasimod (APD334), a potent, selective, oral S1P receptor modulator with preclinical autoimmune disease-modifying activity exhibits favorable PK/PD properties in healthy volunteers
AIBD, 2016Safety, tolerability and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers
ECCO, 2017Early and durable symptom control in patients with moderately-to-severely active ulcerative colitis treated with etrasimod (APD334) in the randomized, double-blind, placebo-controlled, phase 2 OASIS trial and open-label extension
ACG, 2020Early and durable symptom control in patients with moderately-to-severely active ulcerative colitis treated with etrasimod (APD334) in the randomised, double-blind, placebo-controlled, phase 2 OASIS trial and open-label extension
UEG, 2020Histologic remission and mucosal healing in a randomized, placebo-controlled, phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis
DDW, 2019Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis
ECCO, 2019 (J Crohns Colitis, 2019)Safety and efficacy of olorinab, a peripherally acting, highly selective, cannabinoid type 2 receptor agonist in a phase 2a study in chronic abdominal pain associated with Crohn’s disease
DDW, 2019Safety and efficacy of olorinab, a peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2a study in chronic abdominal pain associated with Crohn’s disease
ECCO, 2019Effect of etrasimod on circulating lymphocyte subsets: data from a randomized phase 1 study in healthy Japanese and Caucasian men
Am J Gastroenterol, 2020Effect of etrasimod on circulating lymphocyte subsets: data from a randomized phase 1 study in healthy Japanese and Caucasian men
DDW, 2021DOP078: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation , selective S1P receptor modulator
ECCO, 2017DOP077: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation , selective S1P receptor modulator
ECCO, 2017Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor modulator, in healthy volunteers
ECCO, 2018Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects
J Crohns Colitis, 2020Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects
ECCO, 2020Faecal calprotectin and C-reactive protein levels are correlated with long term clinical and endoscopic outcomes: analysis of the OASIS open label extension trial of etrasimod for ulcerative colitis
ECCO, 2020Fecal calprotectin and C-reactive protein levels are correlated with long term clinical and endoscopic outcomes: analysis of the OASIS open label extension trial of etrasimod for ulcerative colitis
DDW, 2020Correlation of fecal calprotectin and C-reactive protein concentrations with clinical outcomes and endoscopic disease activity in patients with ulcerative colitis receiving induction therapy with etrasimod
Gastroenterology, 2019Correlation of fecal calprotectin and C-reactive protein concentrations with clinical outcomes and endoscopic disease activity in patients with ulcerative colitis receiving induction therapy with etrasimod
DDW, 2019Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study
J Crohns Colitis, 2021Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in participants with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study
ECCO, 2021Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study
UEG, 2021Steady-state trough concentrations and their relationship to selected demographic and clinical response measures in etrasimod-treated patients with moderately-to-severely active ulcerative colitis
WCOG, 2019Steady-state trough concentrations and their relationship to selected demographic and clinical response measures in etrasimod-treated patients with moderately-to-severely active ulcerative colitis
NASPGHAN, 2019Receptor profile and efficacy of etrasimod (APD334), an oral, next-generation sphingosine-1-phosphate receptor modulator in development for ulcerative colitis
UEG, 2016Long-term efficacy and safety of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study
UEG, 2019Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study
J Crohns Colitis, 2021Preclinical and clinical efficacy of olorinab, a peripherally restricted, highly selective full agonist of the cannabinoid receptor 2 for the management of visceral pain in inflammatory bowel disease
UEG, 2019Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis
Gastroenterology, 2020The selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis
J Pharmacol Exp Ther, 2019Sphingosine-1-phosphate lyase inhibition alters the S1P gradient and ameliorates Crohn’s-like ileitis by suppressing thymocyte maturation
Inflamm Bowel Dis, 2020Etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis: results from the phase 2 OASIS trial and open-label extension
UEG, 2021Safety, tolerability, and pharmacokinetics of APD371, a highly selective CB₂ agonist, in healthy adults
APS, 2018
